Project Grant K23DA058077
- This $668,110 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund the development and acceptability testing of a technology-based intervention to reduce cannabis misuse among college students. The project aims to refine an existing intervention that provides information on cannabis products, marketing, laws, and risks to increase young adults' cannabis literacy. The research will involve focus groups with...
- This Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) to the Cambridge Public Health Commission, doing business as the Cambridge Health Alliance, will provide $177,110 to study the impact of cannabis legalization and commercialization on substance use and mental health outcomes among individuals with psychosis. The research will utilize quasi-experimental difference-in-difference methods to analyze data from the Population...
- The National Institute on Drug Abuse (NIDA) awarded a $357,806 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Trustees of Indiana University in Indianapolis. The grant will fund a research study to investigate the neural activity underlying instrumental learning and its relationship to treatment outcomes for adolescent cannabis use disorder (CUD). Specifically, the study aims to: (1) identify associations between CUD symptomatology and neural activity during...
- The National Institute on Drug Abuse (NIDA) awarded a $489,500 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Children's Hospital Corporation, doing business as Boston Children's Hospital, to evaluate the use of remote oral fluid testing to assess cannabis non-use in younger adults aged 18-30 years participating in clinical trials. The project aims to establish valid remote procedures for biological assessment of reduced cannabis use, a key outcome in...
- This $197,640 Project Grant, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports the development and pilot testing of a digital therapeutic called AMP-C. AMP-C targets reward dysfunction in individuals with co-occurring cannabis use disorder and major depressive disorder. The 5-year project, led by Dr. Collins at The General Hospital Corporation (doing business as Massachusetts General Hospital), aims to evaluate the...
- This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $450,313 to evaluate the impact of psychotherapeutic advertising claims on cannabis purchasing behaviors among individuals with symptoms of depression and/or anxiety. The project aims to investigate the influence of psychotherapeutic advertising claims and mental health warning labels on online cannabis purchasing by simulating a...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research to examine the relationship between cannabis use and daily functioning in young adults with chronic pain. The $153,000 grant, awarded to Washington State University, will utilize a 6-month longitudinal study design to capture real-time data on cannabis use, pain perception, and functional outcomes like physical activity and sleep in...
- This $196,236 Project Grant, awarded by the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs), will support research to investigate the mechanisms contributing to preconceptions about individuals who use cannabis, especially during pregnancy. The key objectives are to: Leverage natural language processing/artificial intelligence (NLP/AI) techniques to examine preconceptions about cannabis use in clinical notes. Investigate associations between cannabis use...
- This federal Project Grant award of $686,692 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports a study to assess the potential benefits of reduced cannabis consumption for adults with cannabis use disorder (CUD). The study will conduct an 8-week cannabis use reduction trial, where participants receive comprehensive CUD treatment including cognitive behavioral therapy, motivational interviewing, and incentives for...
- This $194,098 Project Grant award under the National Institute on Drug Abuse's (NIDA) Drug Use and Addiction Research Programs (CFDA 93.279) is designed to provide the principal investigator, Dr. Erath, with mentored training in implementation science to become an independent investigator focused on advancing the implementation of evidence-based treatments for stimulant use disorder and other substance use disorders in harm reduction and community treatment settings. The key objectives of the...
DEVELOPMENT OF A NOVEL CANNABIS BRIEF INTERVENTION FOR FREQUENTLY-USING EMERGING ADULTS - PROJECT SUMMARY/ABSTRACT THE OVERALL AIM OF THE PROPOSED K23 MENTORED PATIENT-ORIENTED RESEARCH CAREER DEVELOPMENT AWARD IS TO PROVIDE DR. GEX WITH THE TRAINING AND RESEARCH ACTIVITIES NEEDED TO BECOME AN INDEPENDENT INVESTIGATOR. HER PROGRAM OF RESEARCH WILL FOCUS ON DEVELOPING AND DELIVERING NOVEL BRIEF INTERVENTIONS FOR PROBLEMATIC SUBSTANCE USE AND INCREASING ACCESSIBILITY AND UPTAKE OF EFFICACIOUS INTERVENTIONS. CANNABIS IS THE MOST WIDELY USED FEDERALLY ILLICIT SUBSTANCE AMONG EMERGING ADULTS (AGE 18-25) IN THE U.S., AND FREQUENT CANNABIS USE IS ASSOCIATED WITH MYRIAD LONG-TERM CONSEQUENCES. DESPITE THIS, RATES OF PERCEIVED RISK OF DAILY/REGULAR CANNABIS USE HAVE STEADILY DECLINED OVER THE PAST TWO DECADES. SEVERAL CANNABIS BRIEF INTERVENTIONS HAVE BEEN DEVELOPED AND TESTED TO DATE; HOWEVER, META-ANALYSES INDICATE THAT THE EVIDENCE FOR EFFICACY IS MIXED AND THAT THE QUALITY OF STUDIES IS LOW, SUGGESTING THAT NOVEL AND MORE RIGOROUS APPROACHES ARE NECESSARY. THE PROPOSED PROJECT WILL EMPLOY THE NIH STAGE MODEL FOR BEHAVIORAL INTERVENTION DEVELOPMENT TO DEVELOP AND TEST THE FEASIBILITY, ACCEPTABILITY, AND PRELIMINARY EFFICACY OF A NOVEL BRIEF INTERVENTION. IN ADDITION, CANNABIS-SPECIFIC CANDIDATE MECHANISMS OF BEHAVIOR CHANGE WILL BE EXPLORED, INCLUDING MOTIVES FOR USE, PROTECTIVE BEHAVIORAL STRATEGIES, CONSIDERATION OF FUTURE CONSEQUENCES, AND PROPORTIONAL SUBSTANCE-FREE/-RELATED REINFORCEMENT. THIS INNOVATIVE PROPOSAL INCLUDES TRAINING ACTIVITIES TO ENSURE THAT DR. GEX ACHIEVES THE FOLLOWING NEW CAREER GOALS: (1) DEVELOP EXPERTISE IN THE ASSESSMENT AND PREVENTION OF CANNABIS USE AND CANNABIS USE DISORDER; (2) RECEIVE TRAINING IN THE DEVELOPMENT AND EVALUATION OF BEHAVIORAL INTERVENTIONS BY (2A) ENHANCING QUALITATIVE AND MIXED METHODS RESEARCH SKILLS AND (2B) RECEIVING ADVANCED TRAINING IN THE DESIGN AND IMPLEMENTATION OF CLINICAL INTERVENTION TRIALS; (3) DEVELOP EXPERTISE IN THE SCIENCE OF MECHANISMS OF BEHAVIOR CHANGE; AND (4) ENHANCE SKILLS IN SCIENTIFIC AND GRANT WRITING AND PROFESSIONAL DEVELOPMENT. UNDER THE MENTORSHIP OF A MULTIDISCIPLINARY TEAM OF OUTSTANDING INVESTIGATORS (DRS. KEVIN GRAY, RACHEL TOMKO, AND SHANNON PHILLIPS AT THE MEDICAL UNIVERSITY OF SOUTH CAROLINA, DR. CHRISTINE LEE AT THE UNIVERSITY OF WASHINGTON, AND DR. BEN LADD AT WASHINGTON STATE UNIVERSITY), THE CANDIDATE WILL DEVELOP AND EVALUATE A NOVEL IN-PERSON BRIEF INTERVENTION ADDRESSING FREQUENT CANNABIS USE IN EMERGING ADULTS. THE COMBINATION OF OUTSTANDING MENTORSHIP, HANDS-ON EXPERIENCES, AND DIDACTICS AND FORMAL COURSEWORK AFFORDED BY THE PROPOSED K23 AWARD WILL SIGNIFICANTLY ENHANCE THE CANDIDATE'S CAREER DEVELOPMENT IN PATIENT-ORIENTED RESEARCH FOCUSED ON THE PREVENTION AND EARLY INTERVENTION OF SUBSTANCE USE DISORDERS IN EMERGING ADULTS AND WILL PROVIDE A VALUABLE TRAINING EXPERIENCE AND CRITICAL PRELIMINARY DATA TO SUPPORT FUTURE R- SERIES APPLICATIONS. THIS K23 APPLICATION IS DIRECTLY RESPONSIVE TO NIDA'S STRATEGIC PLAN TO DEVELOP NEW AND IMPROVED STRATEGIES TO REDUCE CANNABIS USE AND PREVENT LONG-TERM CONSEQUENCES, SPECIFICALLY TO DEVELOP AND TEST INNOVATIVE PREVENTION INTERVENTIONS THAT TARGET RELEVANT MECHANISMS UNDERLYING SALIENT RISK FACTORS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $205.4k | 5/15/25 | ||
| Not listed | $205.4k | 6/5/24 | ||
| Not listed | $205.4k | 6/5/24 |